Phase 2
N=48
Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
Cardiac Arrest
Bottom Line
View on ClinicalTrials.gov: NCT02934555 ↗Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Coenzyme Q10 Plasma Levels — 185; 207; 113; 441 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Ubiquinol (Drug); Ensure (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Beth Israel Deaconess Medical Center
- Primary completion
- May 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Coenzyme Q10 Plasma Levels |
185; 207; 113; 441; 148; 615 | — |
| SECONDARY Decreased Neurological Injury |
7.6; 9.2; 8.2; 16.8; 5.3; 12.6 | — |
| SECONDARY Cellular Oxygen Consumption |
7.6; 6.5; 20.7; 18.0 | — |
| SECONDARY Global Oxygen Consumption |
3.1; 3.5; 3.2; 3.5; 3.8; 4.4 | — |
| SECONDARY Mortality |
14; 15 | — |
| SECONDARY Number of Participants With Favorable Neurological Outcome |
8; 9 | — |
Summary
To study the effects of ubiquinol as a "metabolic resuscitator" in post-cardiac arrest.
Eligibility Criteria
Inclusion Criteria
- Adult (≥ 18 years)
- Cardiac arrest defined by cessation of pulse requiring chest compressions
- Not following commands after ROSC
- Admission to the ICU
- Naso/orogastric tube
- Ability to receive enteral medication
Exclusion Criteria
- Protected populations (pregnant women, prisoners, the intellectual disabled)
- Current CoQ10 supplementation
- Anticipated death within 24 hours
- > 12 hours from ROSC to estimated randomization
- Jejunostomy tube (J-tube)
Data sourced from ClinicalTrials.gov (NCT02934555). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.